<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2018-04246-998-12263</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Epigenetic alterations in the immune defense in tuberculosis-exposed individuals</narrative>
   <narrative xml:lang="SV">Epigenetiska f&#xF6;r&#xE4;ndringar i immunf&#xF6;rsvaret hos tuberkulos-exponerade individer</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Tuberculosis (TB) remains one of the major health challenges of our time. Control of this epidemic is hampered by the lack of an effective vaccine and emergence of multi-drug resistance. This project addresses the question of how the immune system is altered epigenetically due to TB exposure in both peripheral blood and in the lungs. The project builds on our previous studies, in which we demonstrate that mycobacterial exposure triggers epigenetic changes in immune cells. In the present study we will 1) use an existing collection of cryo-preserved immune cells isolated from TB-exposed individuals area in order to identify an epigenetic biosignature that reflects TB exposure, 2) investigate the epigenomes in immune cells of health care workers before and after a year of medical residency in high-endemic areas to validate the finding and &#xA0;3) map the epigenome of immune cells isolated from TB-patients and their household contacts and investigate whether the biosignature is useful as a biomarker to discriminate these exposed individuals from unexposed controls. The results will enhance the understanding of how natural exposure to TB affects lung immunity and the generated knowledge will have importance for guiding the development of novel strategies for prevention, diagnosis and prediction of treatment outcome.</narrative>
   <narrative xml:lang="SV">Tuberkulos orsakas av en bakterie och med 10 miljoner insjuknande och 2 miljoner d&#xF6;da varje &#xE5;r &#xE4;r sjukdomen en av v&#xE5;r tids st&#xF6;rsta globala hot. Tuberkulos kr&#xE4;ver l&#xE5;ngvarig behandling och om man drabbas av antibiotikaresistent tuberkulos &#xE4;r behandlingstiden tv&#xE5; &#xE5;r med sv&#xE5;ra biverkningar. Tuberkulosbakterien &#xF6;verlever inuti vita blodkroppar (immunceller) som finns i lungan. Dessa celler har normalt f&#xF6;rm&#xE5;ga att avd&#xF6;da bakterier, men denna f&#xF6;rm&#xE5;ga h&#xE4;mmas av tuberkelbakterien. Ett viktigt forskningsm&#xE5;l idag &#xE4;r att, utveckla ett effektivt vaccin som f&#xF6;rebygger tuberkulosinfektion. Detta skulle p&#xE5; sikt kunna m&#xF6;jligg&#xF6;ra att sjukdomen utrotas. Liksom traditionell vaccinutveckling, inriktas alla p&#xE5;g&#xE5;ende tuberkulos-vaccinstudier mot att skr&#xE4;ddarsy ett s&#xE5; kallat f&#xF6;rv&#xE4;rvat immunf&#xF6;rsvar mot tuberkulosbakterier. Detta tillv&#xE4;gag&#xE5;ngss&#xE4;tt bygger p&#xE5; antaganden kring infektionen, som till exempel att ett tidigare insjuknande skulle g&#xF6;ra individen immun mot att f&#xE5; sjukdomen igen. Men d&#xE5; det g&#xE4;ller tuberkulos &#xE4;r det vanligt att man f&#xE5;r sjukdomen igen n&#xE4;r man blir smittad p&#xE5; nytt. D&#xE4;remot &#xE4;r det bara en av tio smittade individer som utvecklar aktiv sjukdom och grunden f&#xF6;r v&#xE5;r forskning &#xE4;r att f&#xF6;rs&#xF6;ka f&#xF6;rst&#xE5; hur exponerade individer klarar av att helt oskadligg&#xF6;ra bakterierna. V&#xE5;ra fr&#xE5;gest&#xE4;llningar handlar om att f&#xF6;rs&#xF6;ka f&#xF6;rklara hur s&#xE5; kallade epigenetiska mekanismer kan p&#xE5;verka v&#xE5;rt immunf&#xF6;rsvar s&#xE5; att vi skyddas mot tuberkulos. Epigenetik handlar om att det genetiska materialet kan sl&#xE5;s p&#xE5; och av med hj&#xE4;lp av kemisk modifiering av DNA-stegen, och att celler kan f&#xF6;r&#xE4;ndra sitt aktiveringsm&#xF6;nster med hj&#xE4;lp av s&#xE5;dana kemiska modifikationer. Detta &#x201D;epigenetiska immunminne&#x201D;, som vi kunnat identifiera, &#xE4;r helt annorlunda &#xE4;n det immunminne som ligger till grund f&#xF6;r samtliga existerande vacciner. Denna banbrytande uppt&#xE4;ckt kr&#xE4;ver ytterligare studier f&#xF6;r att bereda v&#xE4;g f&#xF6;r ett nytt s&#xE4;tt att utveckla strategier f&#xF6;r att skydda individer fr&#xE5;n tuberkulossmitta. Under projektet kommer vi att 1) genom moderna metoder som omfattar hela genomet identifiera ett epigenetiskt m&#xF6;nster i immunceller isolerade fr&#xE5;n v&#xE5;rdpersonal f&#xF6;re och efter de arbetar i ett omr&#xE5;de d&#xE4;r tuberkulos &#xE4;r vanligt, vilket inneb&#xE4;r att de kan ha utsatts f&#xF6;r tuberkulossmitta och 2) studera om denna s&#xE5; kallade biosignatur kan &#xE5;terfinnas hos tuberkulospatienters n&#xE4;ra kontaktpersoner som utsatts f&#xF6;r smitta men inte blivit sjuka. Projektet f&#xF6;rv&#xE4;ntas f&#xE5; betydelse f&#xF6;r utveckling av ny f&#xF6;rst&#xE5;else f&#xF6;r hur tuberkulos kan f&#xF6;rebyggas och hur en epigenetisk biosignatur kan anv&#xE4;ndas f&#xF6;r diagnostik och prognos inom tuberkulosv&#xE5;rden.</narrative>
  </description>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">Link&#xF6;pings universitet</narrative>
  </participating-org>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2018-11-30" type="1"></activity-date>
  <activity-date iso-date="2022-12-31" type="3"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-region code="998" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Developing countries, unspecified</narrative>
  </recipient-region>
  <sector code="122" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Basic Health</narrative>
  </sector>
  <sector code="12263" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Tuberculosis control</narrative>
  </sector>
  <tag code="3.3" vocabulary="3">
   <narrative xml:lang="EN">3.3 - By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases.</narrative>
   <narrative xml:lang="SV">3.3 - Senast 2030 utrota epidemierna av aids, tuberkulos, malaria och f&#xF6;rsummade tropiska sjukdomar samt bek&#xE4;mpa hepatit, vattenburna sjukdomar och andra smittsamma sjukdomar.</narrative>
  </tag>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2018-12-28"></period-end>
   <value currency="USD" value-date="2018-01-01">149590.3525729541</value>
  </budget>
  <budget>
   <period-start iso-date="2019-01-01"></period-start>
   <period-end iso-date="2019-12-28"></period-end>
   <value currency="USD" value-date="2019-01-01">158631.119195423</value>
  </budget>
  <budget>
   <period-start iso-date="2020-01-01"></period-start>
   <period-end iso-date="2020-12-28"></period-end>
   <value currency="USD" value-date="2020-01-01">130297.4038242288</value>
  </budget>
  <budget>
   <period-start iso-date="2021-01-01"></period-start>
   <period-end iso-date="2021-12-28"></period-end>
   <value currency="USD" value-date="2021-01-01">130297.4038242288</value>
  </budget>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-01-28"></transaction-date>
   <value currency="USD" value-date="2018-01-28">149590.3525729541</value>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2018-11-30"></transaction-date>
   <value currency="USD" value-date="2018-11-30">598361.4102918162</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-01-28"></transaction-date>
   <value currency="USD" value-date="2019-01-28">158631.119195423</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-01-28"></transaction-date>
   <value currency="USD" value-date="2020-01-28">130297.4038242288</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-01-28"></transaction-date>
   <value currency="USD" value-date="2021-01-28">43432.4679414096</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
